This is a multicenter, stratified, randomized, open-label comparator-controlled, Phase III study in patients with somatostatin receptor positive, well-differentiated G2 and G3, advanced GEP NETs, diagnosed within 6 months prior to screening, comparing treatment with Lutathera (7.4GBq/200 mCi x 4 administrations every 8± 1 weeks; cumulative dose: 29.6 GBq/800mCi) plus octreotide long-acting (30 mg every 8 weeks during Lutathera treatment and every 4 weeks after last Lutathera treatment) and high dose octreotide long-acting (60 mg every 4 weeks). - NETTER-2

Advanced Accelerator Applications SA0 个研究点目标入组 222 人开始时间: 2019年10月21日最近更新: 2019年12月16日

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方: Advanced Accelerator Applications SA
入组人数: 222

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•1. Presence of metastasized or locally advanced, inoperable (curative intent) histologically proven, well differentiated Grade 2 or Grade 3 gastroenteropancreatic neuroendocrine (GEP-NET) tumor diagnosed within 6 months prior to screening.
•2. Ki67 index =10 and = 55%.
•3. Patients =15 years of age and a body weight of >40 kg at screening.
•4. Expression of somatostatin receptors on all target lesions documented by CT/MRI scans, assessed by the following somatostatin receptor imaging (SRI) modalities within 3 months prior to randomization: [68Ga]-DOTA-TOC (e.g. Somakit-TOC®) PET/CT imaging or [68Ga]-DOTA-TATE PET/CT imaging (e.g. NETSPOT®) or Somatostatin Receptor scintigraphy (SRS) with 111In-pentetreotide (Octreoscan® SPECT/CT).
•5. The tumor uptake observed in the target lesions must be > normal liver uptake observed on planar imaging.
•6. Karnofsky Performance Score (KPS) =60.
•7. Presence of at least 1 measurable site of disease.
•8. Patients who have provided a signed informed consent form to participate in the study, obtained prior to the start of any protocol related activities.
•Are the trial subjects under 18? yes
•Number of subjects for this age range: 10
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 100
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 112

排除标准

•1. Creatinine clearance <40 mL/min calculated by the Cockroft Gault method.
•2. Hb concentration <5.0 mmol/L (<8.0 g/dL); WBC <2x10^9/L (2000/mm^3); platelets <75x10^9/L (75x10^3/mm^3).
•3. Total bilirubin >3 x ULN.
•4. Serum albumin <3.0 g/dL unless prothrombin time is within the normal range.
•5. Pregnancy or lactation.
•6. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, are not allowed to participate in this study UNLESS they are using highly effective methods of contraception throughout the study and for 6 months after study drug discontinuation.
•7. Peptide receptor radionuclide therapy (PRRT) at any time prior to randomization in the study.
•8. Documented RECIST progression to previous treatments for the current GEP-NET at any time prior to randomization.
•9. Patients for whom in the opinion of the investigator other therapeutic options (eg chemo-, targeted therapy) are considered more appropriate than the therapy offered in the study, based on patient and disease characteristics.
•10. Any previous therapy with Interferons, Everolimus (mTOR-inhibitors), chemotherapy or other systemic therapies administered for more than 1 month and within 12 weeks prior to randomization in the study.
•11. Any previous radioembolization, chemoembolization and radiofrequency ablation.
•12. Any surgery within 12 weeks prior to randomization in the study.
•13. Known brain metastases, unless these metastases have been treated and stabilized for at least 24 weeks, prior to screening in the study. Patients with a history of brain metastases must have a head CT with contrast to document stable disease prior to randomization in the study.
•14. Uncontrolled congestive heart failure (NYHA II, III, IV). Patients with history of congestive heart failure who do not violate this exclusion criterion will undergo an evaluation of their cardiac ejection fraction prior to randomization, preferably via gated equilibrium radionuclide ventriculography. The results from an earlier assessment (not exceeding 30 days prior to randomization) may substitute the evaluation at the discretion of the Investigator, if no clinical worsening is noted. The patient’s measured cardiac ejection fraction in these patients must be >40% before randomization.
•15. QTcF > 470 msec for females and QTcF > 450 msec for males or congenital long QT syndrome.
•16. Uncontrolled diabetes mellitus as defined by a fasting blood glucose >2 ULN.
•17. Hyperkaleamia >6.0 mmol/L (CTCAE Grade 3) which is not corrected prior to study enrolment.
•18. Any patient receiving treatment with short-acting octreotide, which cannot be interrupted for 24 h before and 24 h after the administration of Lutathera, or any patient receiving treatment with SSAs (eg octreotide long-acting), which cannot be interrupted for at least 6 weeks before the administration of Lutathera, unless the tumor uptake on target lesions observed by study-permitted somatostatin receptor imaging (SRI) modalities during continued long-acting SSA treatment is greater than the liver uptake observed by planar imaging.
•19. Patients with any other significant medical, psychiatric, or surgical condition, currently uncontrolled by treatment, which may interfere with the completion of the study.
•20. Prior external beam radiation therapy to more than 25% of the bone marrow.
•21. Current spontaneous urinary incontinence.
•22. Other known co-existing malignancies except non-melanoma skin cancer and carcinoma in situ

研究者

发起方

Advanced Accelerator Applications SA

相似试验

进行中（未招募）

1 期

A phase III multi-center, randomized, open-label study to evaluate the efficacy and safety of Lutathera in combination with best supportive care octreotide long-acting (30 mg), when given as a 1st line treatment in GEP-NET patients with high proliferation rate tumors (G2 and G3), in comparison to treatment with high dose (60 mg) octreotide long-acting.Patients with somatostatin receptor positive, well-differentiated G2 and G3, advanced GEP NETsMedDRA version: 20.0Level: PTClassification code 10052399Term: Neuroendocrine tumourSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10077559Term: Gastroenteropancreatic neuroendocrine tumour diseaseSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10077560Term: Gastroenteropancreatic neuroendocrine tumor diseaseSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2019-001562-15-FRAdvanced Accelerator Applications SA222

进行中（未招募）

1 期

EUCTR2019-001562-15-GBAdvanced Accelerator Applications SA222

进行中（未招募）

1 期

EUCTR2019-001562-15-ITAdvanced Accelerator Applications SA222

进行中（未招募）

1 期

A multicenter, stratified, open, randomized, comparator-controlled, parallelgroup phase III study. In this study, treatment with 177Lu-DOTA0-Tyr3-Octreotate plus best supportive care (30 mg Octreotide LAR) will be compared to treatment with high dose (60 mg) Octreotide LAR in patients with inoperable, somatostatin receptor positive, histologically proven midgut carcinoid tumours.Patients with inoperable, progressive, OctreoScan® positive, well-differentiated neuroendocrine tumours of the small bowel (midgut carcinoid tumours), who are treated with 20 mg or 30 mg Octreotide LAR every 3-4 weeks at a fixed dose for at least 12 weeks prior to enrollment randomization in the study.MedDRA version: 17.0Level: PTClassification code 10052399Term: Neuroendocrine tumourSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.0Level: LLTClassification code 10062392Term: Carcinoid tumor of the small bowelSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2011-005049-11-BEAdvanced Accelerator Applications280

进行中（未招募）

1 期

EUCTR2011-005049-11-ESAdvanced Accelerator Applications231